Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population
Main finding · Cancer diagnosis in IIM vs general populationResult — go to the resultSPR 1.43 95% CI 1.15–1.77Authors' conclusion
In a tertiary referral center population, anti-TIF1γ was most strongly associated with breast and ovarian cancer. Patients with antisynthetase, anti-MDA-5, or anti-HMGCR antibodies had the same cancer risk as the general population.
Study context
- Population
- Idiopathic inflammatory myopathy (IIM) patients at a single tertiary referral center203 with cancer history studied
- Participants
- 1,172 patients
- Exposure
- Observed cancers in IIM patients vs expected cancers in the general population (SEER)
- IIMn = 1,172
- Outcome
- Cancer risk in IIM relative to the general population (SPR)
Methodological detailssingle-centre, standardised prevalence ratios vs SEER registry, adjusted for calendar year, age, sex, race and ethnicity
- Single-centre
- Standardised prevalence ratios vs SEER registry
- Adjusted for calendar year, age, sex, race and ethnicity
Main finding
Cancer diagnosis in IIM vs general population · median follow-up 5.2 years
SPR
1.43
95% CI 1.15–1.77
P = 0.002
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | SPR (95% CI) | P value |
|---|---|---|
| Ovarian cancer in anti-TIF1γ-positive patients (subgroup) · within 3 years of IIM symptom onset | 18.39 (5.01–47.08) | P < 0.001 |
| Breast cancer in anti-TIF1γ-positive patients (subgroup) · within 3 years of IIM symptom onset | 3.84 (1.99–6.71) | P < 0.001 |
Share of cancers within 3 years of DM onset by autoantibody
- Cancers in anti-TIF1γ-positive patients
- 55% (36 of 66)
- Cancers in anti-Mi-2, anti-SAE or anti-NXP-2 positive patients
- 26% (17 of 66)
Cancer in antisynthetase, anti-MDA-5 or anti-hydroxymethylglutaryl-coenzyme A reductase (anti-HMGCR) antibody-positive patients
- No cancer association, positive or negative
Original publication
Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population. Arthritis Rheumatol. Published 16 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →